Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Sez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil A
In patients with LDL-C 190 mg/dL, with or without clinical ASCVD, who have failed at least 2 (and preferably 3) statins, including a trial of 1 attempt at the lowest approved daily dose or using alternative statin dosing, or who still have not achieved adequate reduction in LDL-C or nonHDL-C on maximally tolerated statin therapy, a trial of either ezetimibe or a PCSK9 mAb may be considered as first-line nonstatin therapy (see Figure 7)
Blood pressure, blood sugar, and nutritional intake may shift as you lose weight
Protein was induced with 1 mM IPTG after cells reached an absorbance of 0.5 at 595 nm
US$ 27.00
US$ 26.26
US$ 26.62
US$ 23.98
